Fenton Mary Kay 4
4 · Talaris Therapeutics, Inc. · Filed Feb 2, 2022
Insider Transaction Report
Form 4
Fenton Mary Kay
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-02-01+200,000→ 200,000 totalExercise: $9.10Exp: 2032-01-31→ Common Stock (200,000 underlying) - Award
Common Stock
2021-12-31$13.00/sh+1,000$13,000→ 1,000 total
Footnotes (2)
- [F1]These shares were acquired by the reporting individual under the issuer's 2021 Employee Stock Purchase Plan ("ESPP") in a transaction exempt under Rule 16b-3(c).
- [F2]The shares underlying this option shall vest as follows: 25% shall vest on February 1, 2023; and the remaining shall vest in 36 equal monthly installments thereafter.